AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-09-28 View volume: 11
Antibody–drug conjugates (ADCs) combine the targeting precision of monoclonal antibodies with the cytotoxic potency of small-molecule payloads. The linker connecting the two components is far from passive — it determines stability in circulation, release mechanism at the target site, and the drug-to-antibody ratio (DAR). This guide covers the major linker and payload classes, conjugation strategies, and how each design choice impacts ADC performance.
Every ADC consists of three elements: the antibody (targeting vehicle), the linker (tether and release mechanism), and the payload (cytotoxic drug). The antibody is selected for high affinity and specificity to a tumor-associated antigen that is internalized upon binding. The linker must be stable enough in systemic circulation to prevent premature payload release (which causes off-target toxicity) yet labile enough to release the payload efficiently once inside the target cell. The payload is typically a potent cytotoxin — active at picomolar to low nanomolar concentrations — because only a fraction of administered ADC molecules reach the tumor and are internalized.
| Linker Type | Release Mechanism | Advantages | Limitations |
|---|---|---|---|
| Cleavable — protease-sensitive (Val-Cit, Val-Ala) | Cathepsin B cleavage in lysosome | Efficient intracellular release; bystander killing of adjacent antigen-negative cells | Potential cleavage in tumor microenvironment (extracellular cathepsins) |
| Cleavable — acid-labile (hydrazone) | Hydrolysis at low pH (lysosome pH ~4.5–5.0) | Simple chemistry | Limited plasma stability; largely superseded by protease linkers |
| Cleavable — disulfide | Glutathione-mediated reduction in cytoplasm | Exploits intracellular reducing environment | Stability varies with steric shielding; can be reduced in circulation |
| Non-cleavable (thioether, e.g., MCC) | Complete antibody degradation in lysosome releases payload–amino acid conjugate | Superior plasma stability; no bystander killing (charged metabolite cannot cross membranes) | Requires target internalization; no bystander effect for heterogeneous tumors |
Tubulin inhibitors: Maytansinoids (DM1, DM4) and auristatins (MMAE, MMAF) block microtubule polymerization, arresting cells in mitosis. These are the most clinically validated payloads, used in approved ADCs including brentuximab vedotin (MMAE) and trastuzumab emtansine (DM1).
DNA-damaging agents: Calicheamicin, pyrrolobenzodiazepines (PBDs), and duocarmycins act on DNA through strand scission or cross-linking. More potent than tubulin inhibitors (active at sub-picomolar concentrations), enabling lower DAR ADC designs. Trastuzumab deruxtecan uses a topoisomerase I inhibitor (DXd) and has demonstrated clinical efficacy with a bystander effect.
Emerging payloads: Immune-stimulating payloads (STING agonists, TLR agonists) turn the ADC into a targeted immune activator rather than a cytotoxin. Protein-degrader payloads (PROTACs conjugated to antibodies) and RNA-based payloads are in early development.
Conjugation chemistry determines DAR distribution and homogeneity, which directly impact pharmacokinetics and therapeutic index:
Cysteine conjugation (conventional): Partial reduction of interchain disulfide bonds exposes reactive thiols for maleimide coupling. Produces a heterogeneous mixture (DAR 0–8) centered around DAR 4. This approach is used in brentuximab vedotin.
Lysine conjugation: Acylation of surface-exposed lysine ε-amino groups. Even more heterogeneous than cysteine conjugation (~70 reactive lysines per IgG), producing DAR 0–8+ with broad distribution. Used in trastuzumab emtansine.
Site-specific conjugation: Engineered cysteines (THIOMAB), unnatural amino acids, enzymatic conjugation (transglutaminase, sortase), or glycan-based conjugation (GlycoConnect) enable precisely defined DAR (typically DAR 2 or DAR 4) with homogeneous conjugation sites. Site-specific ADCs consistently show improved therapeutic indices in preclinical studies compared to heterogeneous conjugates.
After ADC internalization and payload release, a membrane-permeable payload can diffuse out of the target cell and kill neighboring antigen-negative cells. This bystander effect is clinically important for heterogeneous tumors where not all cells express the target antigen. Cleavable linkers with hydrophobic payloads (e.g., MC-vc-PAB-MMAE) maximize bystander killing. Non-cleavable linkers release charged payload metabolites that cannot cross cell membranes, eliminating the bystander effect — desirable when specificity is prioritized over broad tumor killing. The choice between cleavable and non-cleavable linkers is therefore a deliberate therapeutic strategy decision, not merely a chemistry preference.
• Tumor biology: Heterogeneous antigen expression → cleavable linker with bystander-permeable payload. Uniform expression → non-cleavable linker is viable.
• Target internalization rate: Rapid internalizers allow both linker types. Slowly internalized targets benefit from cleavable linkers that can release payload in the tumor microenvironment.
• Therapeutic window: Non-cleavable linkers generally have better plasma stability and wider therapeutic windows. If off-target toxicity is a concern, start with non-cleavable.
• Antibody properties: The antibody component must retain binding affinity after conjugation. High-DAR conjugation can sterically impair antigen binding or accelerate clearance. Test conjugated antibody binding by SPR to confirm KD is not significantly shifted.
Developing an ADC program? AtaGenix provides the antibody component — from target discovery through lead generation and engineering — optimized for conjugation compatibility.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-65523339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
